. Scaly erythematous plaques that appeared 3 days after the administration of docetaxel. We received the patient's consent form about publishing all photographic materials. A 78-year-old man with a 50-year history of psoriasis presented with generalized erythematous scaly plaques involving the scalp and face (Fig. 1) . Over 5 years, the psoriasis had been confined to the hands and feet and controlled using topical agents alone. Three days prior to emergence of the rash, he reported being administered the first dose of docetaxel 90 mg as treatment for prostate cancer. No aggravation of the psoriasis had been observed throughout past 4 years of treatment with antiandrogens and radiotherapy. At the present visit, the psoriasis area severity index score was 10.4, and the percentage of body surface area involved was 20%. Given his medical history and clinical features, we concluded that the preexisting psoriasis had exacerbated due to the newly introduced docetaxel treatment. The patient was treated with acitretin at a dose of 20 mg daily and topical calcipotriol/betamethasone dipro-pionate. Docetaxel was discontinued because of a high index of clinical suspicion regarding its role in the aggravation of psoriasis. The psoriasis began to improve, and after 10 weeks of treatment, the patient's condition was controlled without aggravation of the lesions. Docetaxel is one of the most widely used chemotherapeutic agents in recent years. Various cutaneous adverse effects associated with its use include hand-foot syndrome and radiation recall dermatitis 1 . However, only 2 cases of docetaxel-induced psoriasiform eruptions have been reported 2, 3 . These 2 patients demonstrated newly developed psoriasis 2∼4 days after docetaxel administration. Our patient also demonstrated an adverse reaction within 3 days of administration of the docetaxel-only regimen, which led to a high index of clinical suspicion for docetaxel-induced recurrence of psoriasis. The improvement in psoriasis within a short period of acitretin administration after discontinuation of the docetaxel therapy in this patient also strengthens the causal association between docetaxel administration and the aggravation of psoriasis.
To date, the mechanism of docetaxel-induced skin toxicity remains unclear. The occurrence of hand-foot syndrome is explained to be the result of a direct cytotoxic effect of docetaxel 4 . However, some authors suggest that activation of memory-type inflammatory cell causes radiation recall dermatitis 1 . The theory of direct cytotoxicity was not applicable as the causative mechanism involved in the aggravation of psoriasis in our patient. The activation and subsequent role of resident memory T cells could be considered a possible contributory pathomechanism. Through some experiments, docetaxel is known not only to increase the population of CD4 + and CD8 + T-cells but also to augment their functions in mice 5 . As CD4 + and CD8 + T-cells are well known for their role in the pathogenesis of psoriasis, this suggests the possible underlying mechanism of docetaxel-aggravated psoriasis. To our knowledge, no previous reports have described docetaxel-induced aggravation of psoriasis; the 2 aforementioned reports described cases that presented with de novo psoriasis after docetaxel use 2, 3 . Ours is the first report to describe a case of docetaxel-induced aggravation of psoriasis. This case suggests that careful observation is warranted to detect any exacerbation of the disease following docetaxel administration in patients with underlying psoriasis.
